2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Drug Development, Supportive Care, Biological Therapies, Gene Therapy, Non-Biological Therapies, Pharmacology, Women’s Health, Biological Processes, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Genetic Disorders, Metabolic Disorders, Iron Deficiency, Iron Overload, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Pregnant, Animal Model
PAPER

4646 Iron supplementation during pregnancy is associated with lower odds of postpartum depression among individuals with non-anemic iron deficiency

Hui Xiao Chao, MD, PhD, Katherine Zhuo, MD2, Annabel Hagen3, Manoj Menon, MD, MPH4
1 University of Washington, Seattle, Washington, United States
2 University of Washington, Seattle, Washington, United States
3 University of Washington, Seattle, Washington, United States
4 University of Washington, Seattle, Washington, United States

Background:

Postpartum depression (PPD) affects 10–15% of women in the first year postpartum and remains a leading cause of maternal morbidity. Iron deficiency (ID) has been implicated as a risk factor for PPD, but prior studies have largely focused on iron deficiency anemia (IDA). Importantly, non-anemic iron deficiency (NAID), characterized by depleted iron stores despite normal hemoglobin, is now recognized as highly prevalent in pregnancy and may contribute to neurocognitive symptoms and adverse perinatal mental health outcomes. Whether therapeutic iron supplementation is associated with lower PPD risk among individuals with NAID has not been well studied. We investigated whether therapeutic iron supplementation during pregnancy was associated with lower odds of PPD among individuals with NAID.

Methods: This was a single-center retrospective case-control study of patients who delivered at the University of Washington between 2010–2025. Individuals with at least one ferritin measurement obtained during the antepartum or within the 8-week postpartum period were included. PPD status was determined using associated ICD-9 and ICD-10 codes. A total of 288 patients with PPD (cases) and 4,101 patients without PPD (controls) were identified. Propensity score matching at a 1:2 ratio based on age, race, ethnicity, primary language, gestational age at delivery, and date of delivery was performed to select 576 matched controls. Electronic health records were manually reviewed to extract clinical variables, including therapeutic iron intake (therapeutic oral or intravenous iron administered prior to a PPD diagnosis during pregnancy or within 8 weeks postpartum), sociodemographic factors, obstetric and neonatal outcomes, and psychiatric history. ID was defined as the lowest recorded ferritin < 30 ng/mL and anemia as hemoglobin < 11.0 g/dL. Odds ratios (ORs) were calculated using a conditional logistic regression model. Comparisons between groups were performed using chi-square test.

Results: Baseline ID rates were similarly high across the matched cohort (71.8% in PPD vs 74.3% in controls; p=0.47). Similar rates of anemia were also observed (38.9% in PPD vs 37.5% in controls, p=0.11). Among patients with NAID (n=368), oral iron supplementation was associated with significantly lower odds of PPD (OR 0.42, 95% CI: 0.21-0.87, p=0.020), and any iron supplementation (oral or IV) was similarly associated with lower odds of PPD (OR 0.46, 95% CI: 0.24-0.86, p=0.014). Among all iron-deficient individuals (n=622), oral iron and any iron (oral or IV) supplementation showed non-significant trends toward lower odds of PPD (OR 0.70, 95% CI: 0.45-1.09, p=0.118 and OR 0.73, 95% CI: 0.49-1.08, p=0.116, respectively). In contrast, in the subgroup with IDA (n=254), neither oral iron nor any iron supplementation was significantly associated with lower PPD odds (oral iron: OR 0.82, 95% CI: 0.28-2.39, p=0.72; any iron: OR 0.96, 95% CI: 0.34-2.68, p=0.93). There was no significant interaction between treatment and anemia status (oral iron: p=0.12; any iron: p=0.39). Among individuals without ID, neither oral iron nor any iron supplementation was significantly associated with PPD. Notably, patients with NAID were significantly less likely to receive therapeutic iron than those with IDA (62.1% vs 83.8%, p<0.001).

Conclusion: In this retrospective case-control study, therapeutic iron supplementation during pregnancy or postpartum was associated with significantly lower odds of PPD among individuals with NAID, whereas no statistically significant association was observed among individuals with IDA or normal iron status. Among individuals with NAID, oral iron supplementation was associated with 58% reduction in PPD odds, suggesting that iron repletion in individuals with ID, even in the absence of anemia, may reduce the risk of developing PPD. Despite this potential benefit, individuals with NAID were 2.35 times as likely to remain untreated compared with those with IDA. This finding highlights a potential gap in care provided based on anemia status, despite emerging evidence that ID itself may have clinical consequences. Our findings support the growing recognition that ID, even in the absence of anemia, may have clinically important consequences, and treatment of ID may represent a modifiable factor for PPD risk. Future prospective studies are needed to evaluate whether early identification and treatment of NAID during pregnancy can reduce the risk of PPD.

Katherine Zhuo, MD: No relevant conflicts of interest to declare.